Feasibility of delivery of a higher than prescription dose to the dominant intra-prostatic nodule as defined on diffusion contrast-enhanced endo-rectal MRI, while respecting tolerance doses of adjacent normal organs.
Acute toxicity compared to a cohort of 25 patients treated to standard dose
Efficacy will be assessed by repeat DCE MRI at 12 months and TRUS-guided prostate biopsy at 30 months.
40 Years to 80 Years (Adult, Senior)
May 24, 2012
February 22, 2016
Cancer Center for the Southern Interior Kelowna, British Columbia, Canada
† Study has passed its completion date and status has not been verified in more than two years.